XML 60 R31.htm IDEA: XBRL DOCUMENT
v3.20.1

Financing (Tables) | 3 Months Ended
--- | ---
Apr. 03, 2020
Debt Disclosure [Abstract] |
Components Of Debt | The components of the Company’s debt were as follows ($ in millions):
| April 3, 2020 |  | December 31, 2019
Euro-denominated commercial paper (€4.3 billion and €4.6 billion, respectively) | $ | 4,616.0 |  |  | $ | 5,146.2 |
U.S. dollar-denominated commercial paper | 790.2 |  |  | — |
364-day revolving credit facility | — |  |  | — |
Zero-coupon LYONs due 2021 | 33.2 |  |  | 33.6 |
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”) | 276.7 |  |  | 275.8 |
1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”) | 863.8 |  |  | 894.8 |
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”) | 270.1 |  |  | 279.8 |
2.05% senior notes due 2022 (the “2022 Biopharma Notes”) | 697.3 |  |  | 696.9 |
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”) | 554.7 |  |  | 558.9 |
1.7% senior notes due 2024 (€750.0 million aggregate principal amount) (the “2024 Euronotes”) | 805.5 |  |  | — |
5-year revolving credit facility | 2,500.0 |  |  | — |
2.2% senior unsecured notes due 2024 (the “2024 Biopharma Notes”) | 696.2 |  |  | 696.2 |
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”) | 862.6 |  |  | 893.7 |
3.35% senior unsecured notes due 2025 (the “2025 U.S. Notes”) | 497.4 |  |  | 497.3 |
0.2% senior unsecured notes due 2026 (€1.3 billion aggregate principal amount) (the “2026 Biopharma Euronotes”) | 1,343.6 |  |  | 1,392.3 |
2.1% senior notes due 2026 (€500.0 million aggregate principal amount) (the “2026 Euronotes”) | 534.9 |  |  | — |
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”) | 283.4 |  |  | 282.5 |
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”) | 644.7 |  |  | 668.0 |
0.45% senior unsecured notes due 2028 (€1.3 billion aggregate principal amount) (the “2028 Biopharma Euronotes”) | 1,341.7 |  |  | 1,390.1 |
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”) | 219.3 |  |  | 221.0 |
2.6% senior unsecured notes due 2029 (the “2029 Biopharma Notes”) | 794.3 |  |  | 794.8 |
2.5% senior notes due 2030 (€500.0 million aggregate principal amount) (the “2030 Euronotes”) | 535.3 |  |  | — |
0.75% senior unsecured notes due 2031 (€1.8 billion aggregate principal amount) (the “2031 Biopharma Euronotes”) | 1,880.8 |  |  | 1,948.7 |
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”) | 489.3 |  |  | 487.8 |
1.35% senior unsecured notes due 2039 (€1.3 billion aggregate principal amount) (the “2039 Biopharma Euronotes”) | 1,335.1 |  |  | 1,383.6 |
3.25% senior unsecured notes due 2029 (the “2039 Biopharma Notes”) | 888.9 |  |  | 890.3 |
4.375% senior unsecured notes due 2045 (the “2045 U.S. Notes”) | 499.4 |  |  | 499.4 |
1.8% senior unsecured notes due 2049 (€750.0 million aggregate principal amount) (the “2049 Biopharma Euronotes”) | 801.7 |  |  | 830.9 |
3.4% senior unsecured notes due 2049 (the “2049 Biopharma Notes”) | 888.4 |  |  | 890.2 |
Other | 27.0 |  |  | 76.3 |
Total debt | 25,971.5 |  |  | 21,729.1 |
Less: currently payable | 3,234.3 |  |  | 212.4 |
Long-term debt | $ | 22,737.2 |  |  | $ | 21,516.7 |
The following summarizes the key terms of the offerings in aggregate (€ in millions):
| Issue Date |  | Aggregate Principal Amount |  | Stated Annual Interest Rate |  | Issue Price (as % of Principal Amount) |  | Maturity Date |  | Interest Payment Dates (in arrears)
2024 Euronotes | March 30, 2020 |  | € | 750.0 |  |  | 1.700 | % |  | 99.931 | % |  | March 30, 2024 |  | March 30
2024 Euronotes | April 8, 2020 |  | € | 150.0 |  |  | 1.700 | % |  | 100.298 | % |  | March 30, 2024 |  | March 30
2026 Euronotes | March 30, 2020 |  | € | 500.0 |  |  | 2.100 | % |  | 99.717 | % |  | September 30, 2026 |  | September 30
2026 Euronotes | April 8, 2020 |  | € | 300.0 |  |  | 2.100 | % |  | 100.842 | % |  | September 30, 2026 |  | September 30
2030 Euronotes | March 30, 2020 |  | € | 500.0 |  |  | 2.500 | % |  | 99.642 | % |  | March 30, 2030 |  | March 30
2030 Euronotes | April 8, 2020 |  | € | 300.0 |  |  | 2.500 | % |  | 102.166 | % |  | March 30, 2030 |  | March 30
Key Terms of Euronotes Offering | The components of the Company’s debt were as follows ($ in millions):
| April 3, 2020 |  | December 31, 2019
Euro-denominated commercial paper (€4.3 billion and €4.6 billion, respectively) | $ | 4,616.0 |  |  | $ | 5,146.2 |
U.S. dollar-denominated commercial paper | 790.2 |  |  | — |
364-day revolving credit facility | — |  |  | — |
Zero-coupon LYONs due 2021 | 33.2 |  |  | 33.6 |
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”) | 276.7 |  |  | 275.8 |
1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”) | 863.8 |  |  | 894.8 |
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”) | 270.1 |  |  | 279.8 |
2.05% senior notes due 2022 (the “2022 Biopharma Notes”) | 697.3 |  |  | 696.9 |
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”) | 554.7 |  |  | 558.9 |
1.7% senior notes due 2024 (€750.0 million aggregate principal amount) (the “2024 Euronotes”) | 805.5 |  |  | — |
5-year revolving credit facility | 2,500.0 |  |  | — |
2.2% senior unsecured notes due 2024 (the “2024 Biopharma Notes”) | 696.2 |  |  | 696.2 |
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”) | 862.6 |  |  | 893.7 |
3.35% senior unsecured notes due 2025 (the “2025 U.S. Notes”) | 497.4 |  |  | 497.3 |
0.2% senior unsecured notes due 2026 (€1.3 billion aggregate principal amount) (the “2026 Biopharma Euronotes”) | 1,343.6 |  |  | 1,392.3 |
2.1% senior notes due 2026 (€500.0 million aggregate principal amount) (the “2026 Euronotes”) | 534.9 |  |  | — |
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”) | 283.4 |  |  | 282.5 |
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”) | 644.7 |  |  | 668.0 |
0.45% senior unsecured notes due 2028 (€1.3 billion aggregate principal amount) (the “2028 Biopharma Euronotes”) | 1,341.7 |  |  | 1,390.1 |
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”) | 219.3 |  |  | 221.0 |
2.6% senior unsecured notes due 2029 (the “2029 Biopharma Notes”) | 794.3 |  |  | 794.8 |
2.5% senior notes due 2030 (€500.0 million aggregate principal amount) (the “2030 Euronotes”) | 535.3 |  |  | — |
0.75% senior unsecured notes due 2031 (€1.8 billion aggregate principal amount) (the “2031 Biopharma Euronotes”) | 1,880.8 |  |  | 1,948.7 |
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”) | 489.3 |  |  | 487.8 |
1.35% senior unsecured notes due 2039 (€1.3 billion aggregate principal amount) (the “2039 Biopharma Euronotes”) | 1,335.1 |  |  | 1,383.6 |
3.25% senior unsecured notes due 2029 (the “2039 Biopharma Notes”) | 888.9 |  |  | 890.3 |
4.375% senior unsecured notes due 2045 (the “2045 U.S. Notes”) | 499.4 |  |  | 499.4 |
1.8% senior unsecured notes due 2049 (€750.0 million aggregate principal amount) (the “2049 Biopharma Euronotes”) | 801.7 |  |  | 830.9 |
3.4% senior unsecured notes due 2049 (the “2049 Biopharma Notes”) | 888.4 |  |  | 890.2 |
Other | 27.0 |  |  | 76.3 |
Total debt | 25,971.5 |  |  | 21,729.1 |
Less: currently payable | 3,234.3 |  |  | 212.4 |
Long-term debt | $ | 22,737.2 |  |  | $ | 21,516.7 |
The following summarizes the key terms of the offerings in aggregate (€ in millions):
| Issue Date |  | Aggregate Principal Amount |  | Stated Annual Interest Rate |  | Issue Price (as % of Principal Amount) |  | Maturity Date |  | Interest Payment Dates (in arrears)
2024 Euronotes | March 30, 2020 |  | € | 750.0 |  |  | 1.700 | % |  | 99.931 | % |  | March 30, 2024 |  | March 30
2024 Euronotes | April 8, 2020 |  | € | 150.0 |  |  | 1.700 | % |  | 100.298 | % |  | March 30, 2024 |  | March 30
2026 Euronotes | March 30, 2020 |  | € | 500.0 |  |  | 2.100 | % |  | 99.717 | % |  | September 30, 2026 |  | September 30
2026 Euronotes | April 8, 2020 |  | € | 300.0 |  |  | 2.100 | % |  | 100.842 | % |  | September 30, 2026 |  | September 30
2030 Euronotes | March 30, 2020 |  | € | 500.0 |  |  | 2.500 | % |  | 99.642 | % |  | March 30, 2030 |  | March 30
2030 Euronotes | April 8, 2020 |  | € | 300.0 |  |  | 2.500 | % |  | 102.166 | % |  | March 30, 2030 |  | March 30

X
- References No definition available. + Details
Name: | us-gaap_DebtDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(e),(f)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823 Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644 + Details
Name: | us-gaap_ScheduleOfDebtInstrumentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration